Yüklüyor......
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged administration of these inhibitors indicate the need for...
Kaydedildi:
| Yayımlandı: | Front Chem |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7719718/ https://ncbi.nlm.nih.gov/pubmed/33330383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fchem.2020.594619 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|